Literature DB >> 14690773

Psychosis of Alzheimer's disease: clinical characteristics and history.

Lon S Schneider1, Karen S Dagerman.   

Abstract

The concept of psychosis of Alzheimer's disease and dementia is developed with respect to prevalence, incidence, clinical characteristics, clinical course, and potential response to treatment. Psychosis frequently occurs subsequent to the onset of dementia. Published prevalence estimates of psychosis in patients with AD range from 10 to 73% with an overall median of 34% within clinic populations, and from 7 to 20% in community and clinical trials populations depending on definitions used. Among people with AD who have no psychotic symptoms there appears to be an annualized incidence of psychosis of about 20% in outpatients, and a much higher rate in nursing home patients. Female gender, somewhat greater cognitive impairment among outpatients, somewhat lesser cognitive impairment among nursing home patients, and physical aggression are more associated with psychotic signs and symptoms than not. Right frontal hypometabolism and greater frontal neuropsychological deficits occur in AD patients with psychosis in comparison to those without. Among nursing home patients with dementia who have clinically significant agitation, the substantial majority have delusions or hallucinations. Among patients in nursing homes with dementia and psychosis, nearly two-thirds have persistent symptoms over at least 12 weeks, and among outpatient studies, hallucinations and delusions may persist in approximately 40-50% over periods of 3 months to one year. There is some evidence that psychotic symptoms improve modestly with antipsychotic medication treatment. There is sufficient descriptive and empirical research to support the validity of a syndrome of psychosis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14690773     DOI: 10.1016/s0022-3956(03)00092-x

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  11 in total

1.  Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation.

Authors:  Edward Alan Miller; Lon S Schneider; Robert A Rosenheck
Journal:  Int Psychogeriatr       Date:  2010-03-10       Impact factor: 3.878

Review 2.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

3.  Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.

Authors:  Marco Canevelli; Nawal Adali; Christelle Cantet; Sandrine Andrieu; Giuseppe Bruno; Matteo Cesari; Bruno Vellas
Journal:  J Neurol       Date:  2013-03-17       Impact factor: 4.849

4.  Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.

Authors:  Jeremy Koppel; Chris Acker; Peter Davies; Oscar L Lopez; Heidy Jimenez; Miriam Azose; Blaine S Greenwald; Patrick S Murray; Caitlin M Kirkwood; Julia Kofler; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2014-03-06       Impact factor: 4.673

5.  Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease.

Authors:  Michael S Rafii; Curtis S Taylor; Hyun T Kim; Rahul S Desikan; Adam S Fleisher; David Katibian; James B Brewer; Anders M Dale; Paul S Aisen
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-10-27       Impact factor: 2.035

6.  Heme deficiency in Alzheimer's disease: a possible connection to porphyria.

Authors:  Barney E Dwyer; Meghan L Stone; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  J Biomed Biotechnol       Date:  2006

Review 7.  Optimal treatment of Alzheimer's disease psychosis: challenges and solutions.

Authors:  Jeremy Koppel; Blaine S Greenwald
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-24       Impact factor: 2.570

Review 8.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

9.  Neuroprotection by aripiprazole against β-amyloid-induced toxicity by P-CK2α activation via inhibition of GSK-3β.

Authors:  So Youn Park; Hwa Kyoung Shin; Won Suk Lee; Sun Sik Bae; Koanhoi Kim; Ki Whan Hong; Chi Dae Kim
Journal:  Oncotarget       Date:  2017-11-30

10.  Understanding egorrhea from cultural-clinical psychology.

Authors:  Jun Sasaki; Kaori Wada; Yoshihiko Tanno
Journal:  Front Psychol       Date:  2013-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.